Computational insights into harmala alkaloids as novel antimalarial candidates against Plasmodium falciparum

Malaria, caused by the Plasmodium falciparum, remains a significant global health challenge, accounting for approximately 50% of all cases and posing the greatest threat. Despite advances in control measures, malaria continues to cause an estimated one million deaths annually. The complex lifecycle of P. falciparum, involving both vertebrate hosts and anopheline mosquitoes, complicates eradication efforts. The parasite's resistance to existing antimalarial drugs, along with medication toxicity, necessitates innovative therapeutic approaches. Recent research has revealed that harmane, an alkaloid produced by an endophytic gut bacterium of anopheline mosquitoes, Delftia tsuruhatensis TC1, can impede the transmission of the malarial parasite to humans by inhibiting a crucial life stage. This study examines harmala alkaloids, obtained from plants and microbes such as Peganum harmala, as potent metabolites for antimalarial medications. Notably, harmine and harmaline have shown promising antimalarial activity by inhibiting the essential enzyme protein kinase 4 (PK4), which is vital for the parasite's survival. These compounds exhibit lower toxicity, effectively inhibiting both the blood stage growth and transmission of the parasite. Using in silico methodologies, including ADME analysis, molecular docking, MD simulation, and toxicity analysis, this study identifies harmala alkaloids as potential inhibitors against crucial P. falciparum proteins. These findings open up promising avenues for the development of a rationally designed antimalarial drug, addressing the challenges of drug resistance and toxicity, and warrant further in vitro and in vivo validation.